title: Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.
abstract: Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disorder of the brain caused by a ubiquitous polyomavirus, JC virus. PML is almost always associated with some underlying immunosuppression and acquired immune deficiency syndrome has been the most common predisposing disorder. Recently, different pharmacological agents have been demonstrated to increase the risk of PML. Therapies that predispose people to PML can be classified into three categories: therapies that uniquely increase the risk for the disorder, such as the monoclonal antibodies natalizumab and efalizumab; therapies that appear to increase the risk in individuals already at risk of PML due to pre-existing conditions, such as rituximab and mycophenolate mofetil; and therapies with a mechanism of action that might suggest a potential for increased PML risk and/or with which rare cases of PML have been observed. Unlike the latter two classes, therapeutic agents uniquely increasing the risk of PML are associated with a much greater prevalence of the disorder and a latent interval from the time of drug initiation to the development of PML. PML development with pharmacological agents has provided new insight into the pathogenesis of this devastating disorder. This review focuses on the risks of PML with multiple pharmacological agents, the proposed pathogenesis with these agents, and potential risk mitigation strategies.
authors.affiliation: Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, USA.
authors.forename: Fariha
authors.initials: F
authors.lastname: Zaheer
authors.affiliation: Department of Neurology, University of Kentucky, Kentucky Clinic Room L-445, 740 S. Limestone St., Lexington, KY 40536, USA.
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Berger
keywords: JC virus; alemtuzumab; efalizumab; multiple sclerosis; mycophenolate mofetil; natalizumab; progressive multifocal leukoencephalopathy; rituximab
references.citation: J Med Virol. 2003 Sep;71(1):115-23
references.pmid: 12858417
references.citation: Br J Dermatol. 2001 Jun;144(6):1114-20
references.pmid: 11422029
references.citation: Arch Neurol. 2008 Dec;65(12):1596-603
references.pmid: 18852339
references.citation: J Neuroimmunol. 2008 Feb;194(1-2):153-64
references.pmid: 18178259
references.citation: J Neurovirol. 2002 Dec;8 Suppl 2:115-21
references.pmid: 12491162
references.citation: Drugs Today (Barc). 2009 Jul;45(7):521-32
references.pmid: 19834629
references.citation: Lancet. 1971 Jun 19;1(7712):1257-60
references.pmid: 4104715
references.citation: J Invest Dermatol. 2003 Dec;121(6):1383-8
references.pmid: 14675187
references.citation: N Engl J Med. 2009 Sep 10;361(11):1081-7
references.pmid: 19741229
references.citation: Ann Neurol. 2011 Nov;70(5):742-50
references.pmid: 22162056
references.citation: J Med Virol. 2010 Mar;82(3):494-504
references.pmid: 20087944
references.citation: Lancet Neurol. 2007 May;6(5):431-41
references.pmid: 17434098
references.citation: J Neuroimmunol. 2006 Nov;180(1-2):63-70
references.pmid: 16904756
references.citation: Lancet. 2008 Oct 25;372(9648):1463-72
references.pmid: 18970976
references.citation: AIDS. 1992 Aug;6(8):837-41
references.pmid: 1418781
references.citation: JAMA. 2003 Dec 17;290(23):3073-80
references.pmid: 14679270
references.citation: Ann Neurol. 2010 Sep;68(3):295-303
references.pmid: 20737510
references.citation: J Neurovirol. 1999 Apr;5(2):125-33
references.pmid: 10321976
references.citation: J Heart Lung Transplant. 2009 Apr;28(4):395-8
references.pmid: 19332268
references.citation: Arch Neurol. 2010 Aug;67(8):923-30
references.pmid: 20697042
references.citation: Ann Neurol. 2006 May;59(5):743-7
references.pmid: 16634029
references.citation: N Engl J Med. 2003 Nov 20;349(21):2004-13
references.pmid: 14627785
references.citation: Blood. 2009 May 14;113(20):4834-40
references.pmid: 19264918
references.citation: Clin Immunol. 2004 Oct;113(1):38-46
references.pmid: 15380528
references.citation: Rev Neurol (Paris). 2002 Nov;158(11):1121-3
references.pmid: 12451348
references.citation: N Engl J Med. 2005 Jul 28;353(4):362-8
references.pmid: 15947080
references.citation: Br J Dermatol. 2008 May;158(5):1107-16
references.pmid: 18373710
references.citation: J Infect Dis. 2009 Mar 15;199(6):837-46
references.pmid: 19434930
references.citation: Arch Neurol. 2006 Oct;63(10):1383-7
references.pmid: 17030653
references.citation: N Engl J Med. 2005 Jul 28;353(4):369-74
references.pmid: 15947079
references.citation: J Immunol. 2005 Aug 15;175(4):2721-9
references.pmid: 16081850
references.citation: N Engl J Med. 2006 Mar 2;354(9):924-33
references.pmid: 16510746
references.citation: Immunol Today. 1995 Oct;16(10):479-83
references.pmid: 7576051
references.citation: J Neuroimmunol. 2011 Apr;233(1-2):46-53
references.pmid: 21185609
references.citation: Lancet. 1959 Oct 10;2(7102):524-9
references.pmid: 13808583
references.citation: N Engl J Med. 2008 Feb 14;358(7):676-88
references.pmid: 18272891
references.citation: J Drugs Dermatol. 2009 Mar;8(3):215
references.pmid: 19271366
references.citation: J Leukoc Biol. 1999 Apr;65(4):428-38
references.pmid: 10204570
references.citation: Science. 1965 Jun 11;148(3676):1477-9
references.pmid: 14301897
references.citation: Clin Immunol. 2012 Jan;142(1):25-30
references.pmid: 21550857
references.citation: Neurology. 2008 Oct 21;71(17):1350-4
references.pmid: 18936427
references.citation: MAbs. 2009 Nov-Dec;1(6):583-9
references.pmid: 20073129
references.citation: J Invest Dermatol. 2008 May;128(5):1182-91
references.pmid: 18239614
references.citation: Int Immunopharmacol. 2009 Jan;9(1):10-25
references.pmid: 19000786
references.citation: J Am Acad Dermatol. 2011 Sep;65(3):546-551
references.pmid: 21514689
references.citation: Clin Ther. 2005 Sep;27(9):1317-28
references.pmid: 16291408
references.citation: Ther Drug Monit. 1995 Dec;17(6):681-4
references.pmid: 8588241
references.citation: J Neurovirol. 2001 Aug;7(4):345-9
references.pmid: 11517414
references.citation: Exp Oncol. 2011 Dec;33(4):239-41
references.pmid: 22217715
references.citation: J Neurovirol. 2003 Oct;9(5):551-8
references.pmid: 13129769
references.citation: Arthritis Rheum. 2010 Nov;62(11):3191-5
references.pmid: 20722036
references.citation: N Engl J Med. 1988 Feb 4;318(5):301-5
references.pmid: 2827029
references.citation: Nat Immunol. 2005 Dec;6(12):1182-90
references.pmid: 16369557
references.citation: Arch Dermatol. 2009 Aug;145(8):937-42
references.pmid: 19687432
references.citation: Neurol Clin. 1984 May;2(2):299-313
references.pmid: 6503939
references.citation: Leuk Lymphoma. 2012 Nov;53(11):2283-6
references.pmid: 22424602
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19057-62
references.pmid: 16380428
references.citation: J Virol. 1998 Dec;72(12):9918-23
references.pmid: 9811728
references.citation: Dermatol Ther. 2004;17(5):393-400
references.pmid: 15379774
references.citation: N Engl J Med. 2005 Jul 28;353(4):375-81
references.pmid: 15947078
references.citation: Clin Infect Dis. 2006 Jul 1;43(1):16-24
references.pmid: 16758413
references.citation: J Infect Dis. 1997 Sep;176(3):632-6
references.pmid: 9291308
references.citation: Transplantation. 2008 Nov 27;86(10):1474-8
references.pmid: 19034021
references.citation: Brain. 1958 Mar;81(1):93-111
references.pmid: 13523006
references.citation: J Neurosci Res. 1990 Dec;27(4):461-71
references.pmid: 1964178
references.citation: Curr Neuropharmacol. 2009 Mar;7(1):60-4
references.pmid: 19721818
references.citation: Arthritis Res. 2002;4 Suppl 2:S22-8
references.pmid: 12110154
references.citation: J Clin Microbiol. 2000 Jan;38(1):105-9
references.pmid: 10618072
references.citation: Drug Saf. 2010 Nov 1;33(11):969-83
references.pmid: 20925435
references.citation: Blood. 1989 Jul;74(1):19-25
references.pmid: 2473795
references.citation: Clin Infect Dis. 2006 Jul 1;43(1):e9-12
references.pmid: 16758410
references.citation: Autoimmun Rev. 2008 Dec;8(2):144-6
references.pmid: 18700172
references.citation: Hematol Cell Ther. 1999 Aug;41(4):183-6
references.pmid: 10543375
references.citation: Microbiol Immunol. 1982;26(11):1057-64
references.pmid: 6300615
references.citation: Prog Clin Biol Res. 1983;105:107-17
references.pmid: 6304747
references.citation: Arthritis Rheum. 2006 Feb;54(2):613-20
references.pmid: 16447239
references.citation: Am J Hematol. 2005 Dec;80(4):271-81
references.pmid: 16315252
references.citation: Discov Med. 2011 Dec;12(67):495-503
references.pmid: 22204766
references.citation: Neurology. 1991 Nov;41(11):1733-6
references.pmid: 1944901
references.citation: J Neurovirol. 2001 Aug;7(4):311-7
references.pmid: 11517409
references.citation: N Engl J Med. 2003 Jan 2;348(1):68-72
references.pmid: 12510047
references.citation: MAbs. 2010 Nov-Dec;2(6):670-81
references.pmid: 21124072
references.citation: Neurology. 2012 Feb 14;78(7):458-67; discussion 465
references.pmid: 22302546
references.citation: Leuk Lymphoma. 2002 Feb;43(2):433-6
references.pmid: 11999583